Patients with chronic kidney disease and metabolic acidosis treated with sodium bicarbonate experienced decreased risks of a doubling of serum creatinine, initiation of renal replacement therapy, and death.
Outside of clinical trials, targeted therapies for advanced renal cell carcinoma in Medicare patients are associated with modest survival advantages over non-targeted therapies.
Proton pump inhibitor use by patients with CKD stage 3 to 5 is associated with 54% and 35% increased risks of acute kidney injury and death, respectively, a study found.
In a small study, 34% of dialysis patients had vertebral fractures, and patients in the highest tertile of parathyroid hormone level had a nearly 3-fold increased risk of these fractures compared with those in the middle tertile.
New data support aggressive vitamin D repletion to a revised serum 25-hydroxyvitamin D target of at least 51 ng/mL in patients with chronic kidney disease.
